Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Iohexol
Drug ID BADD_D01180
Description Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
Indications and Usage Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.
Marketing Status approved
ATC Code V08AB02
DrugBank ID DB01362
KEGG ID D01817
MeSH ID D007472
PubChem ID 3730
TTD Drug ID D02BLO
NDC Product Code 43228-100; 0407-1413; 71806-141; 0407-1414; 0407-1416; 0407-1415; 0407-1401; 0407-1411; 0407-1412; 65072-0801; 54702-501
UNII 4419T9MX03
Synonyms Iohexol | Iohexol 350 | Nycodenz | Compound 545 | Exypaque | Omnipaque
Chemical Information
Molecular Formula C19H26I3N3O9
CAS Registry Number 66108-95-0
SMILES CC(=O)N(CC(CO)O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dysacusis04.02.03.001--Not Available
Muscle tightness15.05.03.0070.014227%Not Available
Anal sphincter atony17.05.02.009; 07.03.01.0030.007113%Not Available
Idiosyncratic drug reaction08.06.01.002--Not Available
Ventricular hypokinesia02.04.02.013--Not Available
Skin tightness23.03.03.0180.026320%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.010670%Not Available
Conjunctival hyperaemia06.04.01.0040.047660%Not Available
Ear discomfort04.03.01.0050.026320%Not Available
Ear pruritus04.03.01.0110.010670%Not Available
Eye oedema06.08.03.0130.017783%Not Available
Eye pruritus06.04.05.0060.303742%Not Available
Nasal discomfort22.12.03.0120.010670%Not Available
Oral pruritus07.05.05.0020.080381%Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.026320%Not Available
Infusion site pain12.07.05.002; 08.02.05.0140.015649%Not Available
Infusion site swelling12.07.05.003; 08.02.05.0020.015649%Not Available
Type IV hypersensitivity reaction10.01.03.0220.007113%Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.014227%Not Available
Cerebral disorder17.02.10.0170.007113%Not Available
Vulvovaginal pruritus23.03.12.009; 21.08.02.0040.019206%Not Available
Temperature intolerance08.01.09.0220.021340%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.0030.061886%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.197041%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.010670%Not Available
Pulseless electrical activity02.03.04.0200.014227%Not Available
Nuchal rigidity17.05.02.006; 15.05.04.0050.007113%Not Available
Angiopathy24.03.02.007--Not Available
The 11th Page    First    Pre   11 12 13    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene